FINWIRES · TerminalLIVE
FINWIRES

Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target

By

Aktis Oncology (AKTS) has an average rating of buy and mean price target of $34.78, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles